Production of one of the world’s most sought-after drugs for migraine therapy starts in Moscow
13 July 2023
The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova® intended for relief of migraine-associated headaches. The drug is based on the Rizatriptan molecule, which for the first time is fully localized in Russia, from development and manufacturing to introduction in the specialist prescription practice. Rizatriptan is one of the most sought-after molecules in the world for relief and alleviation of migraine symptoms.
Production of one of the world’s most sought-after drugs for migraine therapy starts in Moscow
12 July 2023
The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova intended for relief of migraine-associated headaches. The drug is based on the Rizatriptan molecule, which for the first time is fully localized in Russia, from development and manufacturing to introduction in the specialist prescription practice. Rizatriptan is one of the most sought-after molecules in the world for relief and alleviation of migraine symptoms.
12 April 2023
According to a recent report published by Future Market Insights, The projected growth for vascular dementia treatment market indicates an increase in market value to US$ 5.64 billion in FY 2023, reflecting a year-on-year rise of over 5%. Moreover, the market is expected to grow at a compound annual growth rate (CAGR) of 4.77% during the forecast period from 2023 to 2033, with an estimated market value of US$ 8.99 billion by FY 2033.
NovaMedica will produce migraine drug Relonova in Moscow
23 March 2023
Russia’s pharmaceutical company NovaMedica (a Rusnano portfolio company) has registered Relonova, a drug of its own development, used to relieve headaches during migraine attacks. This is the first rizatriptan-based drug fully localized in the Russian Federation, as the company’s press service told GxP News.
RUSNANO has stopped the exit from a number of critically important assets for the country
10 June 2022
RUSNANO has stopped the withdrawal from a number of critically important assets for the country, which contribute to the provision of infrastructure and form a technological reserve for the Russian industry in mechanical engineering, medicine, chemistry, oil and gas, lighting and electronics, telecommunications, energy, transport and housing. Among them are the companies "Plakart", "Virial", "Optical Fiber Systems", "RM Nanotech", "Profotek", "Russian Quartz", "NEVZ-CERAMICS", "Novomet", "ELVIS NeoTek", "ICE-Energoservice", "NovaMedica", "Pharmsintez" and a number of projects of the RUSNANO-SINTEZ Foundation.
Technopolis Moscow has begun to produce a therapy for dementia
26 April 2022
Technopolis Moscow has begun the production of a new therapy for dementia in Alzheimer’s disease, available in the form of tablets in four dosages. This is reported on the official website of the mayor of Moscow.
NovaMedica launches an innovative Alzheimer’s disease therapy that it has developed
21 April 2022
NovaMedica, a Russian pharmaceutical company (Rusnano’s investment project) has developed and registered an innovative combination of donepezil and memantine molecules, which provides the basis for dementia therapy in Alzheimer’s disease. The drug is registered as MYOREOL®. This is the first combination of this type on the Russian market, as well as in the EAEU and Europe.
Producers criticize excessive pharma market regulation in Russia
28 September 2021
Excessive regulation of the Russian pharmaceutical market and the lack of drug insurance system is leading to a shortage of some vital and effective drugs in the local market, according to recent statements by representatives of producers and analysts.
New Russian proctology medicine makes inroads in EU markets
26 July 2021
NovaMedica, a Russian pharmaceutical company and portfolio project of the national nanotech company Rusnano, has developed what might emerge into a market-winning new drug for colorectal therapy.
31 May 2021
Concern Bayer will expand its portfolio of drugs for the treatment of hemorrhoids with the development of the Russian “NovaMedica” based on nifedipine and lidocaine. The German company already holds about 40% of the market for such funds. Pharmaceutical market experts call the deal one of the rare ones: foreign companies do not often acquire rights to Russian medicines.
NovaMedica team in the TOP 100 INFLUENTIAL PEOPLE IN THE PHARMACEUTICAL BUSINESS 2024
28 November 2024
05 November 2024
03 November 2024
By 2030, Russia aims to produce 90% of essential medicines
09 December 2024
The government allocated more funds for preferential loans on imported medicines and medical devices
06 December 2024
RNC Pharma: Russians’ spending on medicines has reached a historic high
06 December 2024
The government announced a new national project “Bioeconomics”
05 December 2024